News
AACI and Medlive Advance Education on CAR T-Cell Therapy Through Video-Based Learning
AACI is collaborating with Medlive, a leader in expert-guided digital medical education, on a series of educational video initiatives focused on CAR T-cell therapy. This partnership supports AACI’s mission to provide cancer center leaders and care teams with timely, evidence-based education on emerging therapies and evolving models of care in hematologic malignancies.
Through this collaboration, AACI and Medlive have launched three active video-based projects exploring the transformative impact of CAR T-cell therapy. Two of these offerings are CME-accredited and feature multidisciplinary expert perspectives on patient selection, outpatient care strategies, and toxicity management, while the third provides additional expert insights to support team-based, patient-centered care and improved outcomes across care settings.
Community-Driven Navigation of CAR T-Cell Therapy (CME-Accredited Video Series)
This video series examines strategies to expand access to CAR T-cell therapy through community-driven models of care. Expert faculty discuss optimal patient identification and referral, outpatient administration considerations, and multidisciplinary approaches to managing toxicities such as cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS).
Bispecific CAR T-Cell Therapies in LBCL/DLBCL (CME-Accredited Video Series)
Focused on relapsed or refractory large B-cell lymphoma (LBCL) and diffuse large B-cell lymphoma (DLBCL), this video series highlights emerging clinical data on bispecific and dual-targeting CAR T-cell therapies. Faculty explore how these approaches may help overcome resistance, improve durability of response, and inform evolving treatment strategies in clinical practice.
Rewriting the Course: CAR T-Cell Therapy in RRMM – A New Era of Timely, Team-Based, Patient-Centered Care
This video series emphasizes the importance of earlier referral for CAR T-cell therapy in relapsed or refractory multiple myeloma (RRMM). Experts discuss how to identify eligible patients, streamline coordination between community and academic centers, and manage post-infusion care, including CRS and ICANS, within team-based care models.